[Expressions and clinicopathologic significance of Id2 and NF-κB/P65 in gastric cancer].
Objective: To investigate the expressions and clinicopathologic significance of Id2 and NF-κB/P65 in gastric cancer. Methods: Immunohistochemistry was used to detect Id2 and NF-κB/P65 expressions in gastric cancer tissues of 336 cases and paraneoplastic normal mucosa tissues of 60 cases.The expressions of Id2 and NF-κB/P65 in gastric cancer were significantly higher than those in normal mucosa tissues (χ(2)=44.631, P<0.001; χ(2)=34.650, P<0.001). Results: The positive expression rates of Id2 and NF-κB/P65 were 71.4% (240/336) and 56.3% (189/336) in cancer tissues, and 26.7%(16/60) and 15.0%(9/60)in normal tissues, respectively.Id2 and NF-κB/P65 were all related to tumor size, differentiation degree, infiltrative depth, lymphatic invasion, distant metastasis and clinical TNM stage (P<0.05). The 5-year survival rate of the patients with Id2 or NF-κB/P65 expression was lower than that of patients with negative Id2 or NF-κB/P65 expression (χ(2)=52.329, P<0.001; χ(2)=20.525, P<0.001). Id2 expression in gastric cancer was positively correlated with the NF-κB/P65 expression (r=0.292, P<0.001). And the NF-κB/P65 expression in the Id2 positive group is significantly higher than that in the group with negative Id2 (χ(2)=28.681, P<0.001). The final multivariate Cox regression model indicated that Id2 expression was an independent prognostic factor for overall survival after operation (HR=2.327, 95%CI 1.622-3.337, P<0.001). Conclusions: Id2 and NF-κB/P65 may synergistically promote the generation and evolution of gastric cancer, and their co-detection can be of great importance for clinical assessment of tumor biological behavior and prognosis in patients with gastric cancer.